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Abstract
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited cardiac 
arrhythmia syndrome that often leads to sudden cardiac death. The most common 
form of CPVT is caused by autosomal- dominant variants in the cardiac ryanodine 
receptor type- 2 (RYR2) gene. Mutations in RYR2 promote calcium (Ca2+) leak from the 
sarcoplasmic reticulum (SR), triggering lethal arrhythmias. Recently, it was demon-
strated that tetracaine derivative EL20 specifically inhibits mutant RyR2, normalizes 
Ca2+ handling and suppresses arrhythmias in a CPVT mouse model. The objective 
of this study was to determine whether EL20 normalizes SR Ca2+ handling and ar-
rhythmic events in induced pluripotent stem cell- derived cardiomyocytes (iPSC- CMs) 
from a CPVT patient. Blood samples from a child carrying RyR2 variant RyR2 vari-
ant Arg- 176- Glu (R176Q) and a mutation- negative relative were reprogrammed into 
iPSCs using a Sendai virus system. iPSC- CMs were derived using the StemdiffTM kit. 
Confocal Ca2+ imaging was used to quantify RyR2 activity in the absence and pres-
ence of EL20. iPSC- CMs harbouring the R176Q variant demonstrated spontaneous 
SR Ca2+ release events, whereas administration of EL20 diminished these abnormal 
events at low nanomolar concentrations (IC50 = 82 nM). Importantly, treatment with 
EL20 did not have any adverse effects on systolic Ca2+ handling in control iPSC- CMs. 
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1  | INTRODUC TION
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a life- 
threatening inherited cardiac arrhythmia syndrome that can lead to sudden 
cardiac arrest and death at a very high rate if left untreated. It is character-
ized by polymorphic and/or bi- directional ventricular tachycardia (VT) that 
is triggered by β- adrenergic stimulation associated with vigorous exercise 
or emotional stress.1 The prevalence of CVPT is estimated to be around 
1:5000 to 1:10 000; both sexes are affected equally. The most common 
form of CPVT is caused by autosomal- dominant variants in the RYR2 gene 
encoding the cardiac ryanodine receptor type- 2.2,3 The RyR2 channel re-
leases Ca2+ from the sarcoplasmic reticulum (SR) in response to electrical 
excitation of the plasma membrane, which leads to influx of Ca2+ via the 
L- type Ca2+ channel. Variants in RYR2 promote diastolic SR Ca2+ leak which 
causes triggered activity and can initiate arrhythmias seen in CPVT.1,4
Although CVPT is one of the most lethal forms of inherited cardiac 
disease, current treatment options remain limited. β- adrenoreceptor 
blockers only control symptoms and suppress arrhythmias in about 
30%- 50% of patients.5 Flecainide— a class 1C Na+ channel blocker 
that also normalizes RyR2 activity— has shown potential in CPVT 
patients but also has a black box warning for patients with any kind 
of structural heart disease.6,7 Implantable cardioverter- defibrillators 
(ICDs) are used in the event of severe or recurrent arrhythmias, but 
ICD discharges may further aggravate catecholamine release and lead 
to electrical storm.8 Hence, there remains an unmet need to develop 
new pharmacological or biological agents for the treatment of CPVT 
that specifically correct disease- causing molecular defects.
Several classes of drugs have been developed that target mutant 
or dysfunctional RyR2 channels.9 These include, among others, ben-
zothiazepine derivatives (K201, S107),10,11 tetracaine derivatives (EL9, 
EL20),12,13 class 1C anti- arrhythmic drug derivatives of flecainide and 
propafenone,14 hydantoin derivatives (such as dantrolene),15 non- 
beta blocking carvedilol derivatives16 and unnatural verticilide enan-
tiomers.17 The efficacy of these compounds have been evaluated in 
various knock- in mouse models carrying RyR2 variants or calseques-
trin- 2 variants/knockout.11,12,14,18 For example, mice heterozygous for 
RyR2 variant RyR2 variant Arg- 176- Glu (R176Q) are susceptible to 
ventricular tachycardia after injection of caffeine and epinephrine, or 
following programmed ventricular stimulation and administration of 
β- adrenergic receptor agonist isoproterenol (ISO).18
We recently demonstrated that tetracaine derivative EL20 can nor-
malize aberrant SR Ca2+ leak associated with CPVT in the R176Q mouse 
model.13 The half- maximum inhibitory concentration of EL20 in mouse 
myocytes was 35.4 mmol/L,13 which was an order of magnitude better 
than that of another well- studied RyR2 inhibitor JTV519 (K201).12 This tet-
racaine derivative does not block Na+ or IKr channels within the effective 
concentration range used to inhibit RyR2 channels and has a favourable 
plasma stability profile (data not shown). In addition, tetracaine derivatives 
appear to work for all gain- of- function RyR2 variants, which represent the 
vast majority (>95%) of all known CPVT- causing variants (>150 described 
to date). It remains unclear, however, whether a compound like EL20 also 
normalizes CPVT- mutant RyR2 in human cardiac myocytes. Therefore, 
we developed induced pluripotent stem cell- derived cardiomyocytes 
(iPSC- CMs) from a CPVT patient carrying the same R176Q variant in 
RYR2. Confocal imaging revealed that EL20 effectively suppresses the 
enhanced Ca2+ spark frequency observed in iPSC- CMs from this CPVT 
patient. These findings suggest that this RyR2- inhibitor represents a 
promising therapeutic candidate for treatment of CPVT patients.
2  | MATERIAL S AND METHODS
2.1 | Human subject recruitment
All studies were approved by the Baylor College of Medicine IRB 
and follow the Declaration of Helsinki guidelines. Subjects were 
evaluated by a paediatric electrophysiologist and a history, physical 
examination, echocardiogram, electrocardiogram and ancillary test-
ing were performed. Following written receipt of informed consent, 
whole blood was obtained from the proband and kindred.
2.2 | Cardiac differentiation of iPSCs
iPSCs were differentiated into iPSC- CMs using the STEMdiffTM CM dif-
ferentiation kit (Stemcell Technologies) according to the company pro-
tocol (Document #DX21496). See Supplemental Methods for details.
2.3 | Dissociation and plating of mature iPSC- CMs
Spontaneously beating CMs were dissociated using the STEMDiffTM 
Cardiomyocyte Dissociation Kit (Stemcell Technologies; Document 
#DX21497). See Supplemental Methods for details.
Our results show for the first time that tetracaine derivative EL20 normalized SR Ca2+ 
handling and suppresses arrhythmogenic activity in iPSC- CMs derived from a CPVT 
patient. Hence, this study confirms that this RyR2- inhibitor represents a promising 
therapeutic candidate for treatment of CPVT.
K E Y W O R D S
Catecholaminergic polymorphic ventricular tachycardia, induced pluripotent stem cells, 
ryanodine receptors, RyR2, tetracaine, ventricular arrhythmia
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2.4 | EL20 synthesis
The tetracaine derivative, 2- (diethylamino)ethyl 4- butlamino)- 2methoxy-
benzoate, also known as EL20, was synthesized using a two- step synthe-
sis route as previously described by Klipp et al.13
2.5 | Ca2+ imaging of iPSC- CMs and drug treatment 
using EL20
For drug assay studies, iPSC- CMs were incubated with drug (con-
centration range 0.5 nmol/L- 5 μmol/L) for 30 minutes at 37°C. Ca2+ 
sparks were recorded in line- scan mode using a LSM880 confocal 
microscope (Carl Zeiss). CaSpF was assessed with ImageJ software 
using SparkMaster plugin. See Supplemental Methods for details.
2.6 | Statistical analysis
Results are expressed as mean ± SEM. For clustered data in which 
continuous variables were observed, the generalized estimating 
equation was used via SPSS version 24 (IBM) or Prism 8 (GraphPad) 
using an unpaired Student's t test or ANOVA, after performing the 
D’Agostino- Pearson normality test for normal data distribution. 
F I G U R E  1   Pedigree and clinical 
phenotype of catecholaminergic 
polymorphic ventricular tachycardia 
(CPVT) patient: A, 14- year- old proband 
and kindred. The CPVT proband is 
identified by a black arrow, and the R176Q 
variant in RYR2 is denoted by a filled black 
symbol (± represents heterozygosity for 
the R176Q variant). Unaffected family 
members are shown as open symbols. 
Family members with a history of sudden 
cardiac arrest who were not genetically 
tested are shown as striped symbols. Line 
through symbol represents deceased 
family member. B, Schematic of RyR2 
protein highlighting R176Q mutation 
(red). C, Standard resting 12- lead ECG 
of the proband showing normal activity. 
D, Episode of polymorphic ventricular 
ectopy following epinephrine challenge in 
proband
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For multiple group comparison, two- way ANOVA followed by 
Tukey's post- test was used. P < .05 was considered statistically 
significant.
3  | RESULTS
3.1 | Clinical evaluation of CPVT proband
The patient was previously a seemingly healthy female with a 
family history of sudden cardiac death (Figure 1A,B). Her mater-
nal grandmother died postpartum at the age of 23 years, after 
giving birth to the proband's mother. The proband's mother suf-
fered an aborted cardiac arrest at the age of 19 and again at the 
age of 35 that consequently left her in a persistent vegetative 
state. The proband underwent cardiac evaluation at the age of 14 
and was found to have a structurally normal heart with normal bi-
ventricular function by echocardiogram (Figure S1). Her 12- lead 
resting ECGs revealed a normal heart rate (54 beats per minute), 
normal PR interval (144 ms), normal QT interval (410 ms) and a 
normal corrected QT interval (QTc of 389 ms) (Figure 1C). She 
had no prior history of syncope and denied any cardiac symp-
toms. A few months after initial evaluation, the patient suffered 
an aborted cardiac arrest after running home from school. She 
was found to be in ventricular fibrillation with return of sponta-
neous circulation after successful defibrillation. During hospital 
admission, she was noted to have bi- directional premature ven-
tricular contractions during periods of stimulation. Due to sus-
picion of CPVT, she underwent an epinephrine challenge which 
revealed bi- directional VT and was subsequently diagnosed with 
CPVT (Figure 1D). Genetic testing confirmed a heterozygous 
pathogenic missense mutation in RYR2 (c.527G>A, p.Arg176Gln 
and R176Q). The CPVT proband is currently being treated with 
a β- blocker and has an ICD. Her father (41- year- old) is an unaf-
fected family member and is considered a healthy, mutation- 
negative control.
3.2 | Development, characterization and cardiac 
differentiation of iPSCs
Blood from the CPVT proband and mutation- negative fa-
ther was collected, and peripheral blood mononuclear cells 
(PBMCs) were extracted and subsequently reprogrammed 
into iPSCs using Sendai viruses (Figure S2A- D). Both cell lines 
were karyotyped and exhibited normal chromosomal archi-
tectures (Figure S2E). The cells were genetically sequenced 
and the mutant variant (G > A) was found to be present in 
the proband- derived iPSCs but not in those derived from the 
control individual (Figure S2F). The pluripotency of the cells 
was validated using fluorescence- activated cell sorting (FACS) 
(Figure S3). CPVT proband and control- derived iPSCs were dif-
ferentiated into CMs that contracted spontaneously as coordi-
nated sheets observed under light microscopy (Figure S4A,B). 
iPSC- CMs dissociated into single cells from both lines main-
tained spontaneous contraction. qPCR demonstrated down- 
regulation of the pluripotency markers and SOX2 (Tables S1 
and S2; Figure S4C) and up- regulation of the cardiac and Ca2+ 
handling markers (Table S2; Figure S4C). Immunofluorescence 
exhibited positive staining for similar cardiac and ca2+ handling 
markers (Table S3; Figure S4D).
3.3 | CPVT patient- derived iPSC- CMs exhibit 
spontaneous and evoked Ca2+ transients
Previous studies revealed that beating clusters of iPSC- CMs con-
tain a mixture of ventricular, atrial and sinus node- like cell popu-
lations based on their action potential (AP) phenotypes.19 Here, 
we used confocal Ca2+ imaging to characterized intracellular Ca2+ 
handling in dissociated iPSC- CMs that exhibited a ventricular- type 
morphology. About 50% of iPSC- CMs exhibited non- evoked, spon-
taneous rhythmic beating without electrical stimulation (Figure 2A). 
The average spontaneous beating rate of non- evoked iPSC- CMs 
with the R176Q mutation was 80.8 ± 8.4/min vs control iPSC- 
CMs 41.6 ± 8.4/min (P = .002) consistent with being arrhythmic 
(Figure S5). In addition, 60% (6 out of 10 cells) of non- evoked R176Q 
iPSC- CM exhibited irregular Ca2+ waveforms following completion 
of the Ca2+ transient, thus resembling events that could initiate de-
layed afterdepolarizations (DADs). The amplitudes of non- evoked 
Ca2+ transients were similar between the groups (F/F0 in R176Q: 
1.7 ± 0.35 vs control: 1.9 ± 0.33; P = .64) (Figure 2B). The SR Ca2+ 
load assessed by a caffeine dump protocol was found to be simi-
lar between both groups (F/F0 in R176Q: 2.2 ± 0.24 vs control: 
2.6 ± 0.88 and P = .37) (Figure 2C). Next, we performed electrical 
field stimulation to characterize iPSC- CMs that were not spontane-
ously active under baseline conditions. About 75% of the iPSC- CMs 
that did not spontaneously beat at baseline followed the 1- Hz pac-
ing train (Figure 2D); the remainder of the cells did not exhibit SR 
Ca2+ release upon electrical stimulation. While similar number of 
iPSC- CMs with the R176Q variant responded to electrical stimula-
tion, 63% of those iPSC- CMs exhibited aberrant SR Ca2+ release 
patterns characterized by Ca2+ oscillations during the Ca2+ transient 
decay phase, that resemble those seen in conjunction with early 
afterdepolarizations (EADs). Finally, the amplitude of the Ca2+ tran-
sients (F/F0 in R176Q: 1.6 ± 0.21 vs control: 1.6 ± 0.44; P = .94) 
(Figure 2E) and total SR Ca2+ load (F/F0 in R176Q: 2.3 ± 0.36 vs 
control: 2.1 ± 0.43; P = .76) (Figure 2F) was similar amongst the 
groups. Together, these results show that systolic SR Ca2+ handling 
was similar between R176Q and control iPSC- CMS, while aberrant 
diastolic SR Ca2+ release events were seen exclusively in iPSC- CM 
from the CPVT patient.
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3.4 | Isoproterenol generates EADs in R176Q iPSC- 
CMs spontaneous and evoked Ca2+ transients
To simulate β- adrenergic stimulation conditions that provoke ar-
rhythmias in CPVT patients, 100 nmol/L isoproterenol (ISO) was 
added to the iPSC- CMs. Addition of ISO led to a positive chrono-
tropic response compared to baseline conditions, as typically seen 
in healthy iPSC- CMs.20 The average spontaneous beating rate of 
non- evoked iPSC- CMs with the R176Q mutation was 122.3 ± 18.1 
/minutes vs control iPSC- CMs 35.4 ± 5.2 (P = .002). 53% of the 
iPSC- CMs with the R176Q variant exhibited abnormal SR Ca2+ re-
lease events during the final phase of SR Ca2+ reuptake, compared 
to 0% of the control cells (P < .05) (Figure 3A). The amplitudes of 
non- evoked Ca2+ transients were similar between the groups (F/F0 
in R176Q: 1.7 ± 0.45 vs control: 1.9 ± 0.37; P = .78) (Figure 3B). The 
SR Ca2+ load was found to be similar between both groups (F/F0 in 
R176Q: 2.7 ± 0.52 vs control: 3.3 ± 0.42 and P = .53) (Figure 3C).
About 75% of the iPSC- CMs that did not spontaneously beat 
did generate SR Ca2+ transients following the 1- Hz pacing train 
(Figure 3D). While similar number of iPSC- CMs with the R176Q 
variant responded to electrical stimulation, 71% (5 of 7) of those 
iPSC- CMs exhibited distinct oscillating SR Ca2+ release patterns 
that originated early during the Ca2+ transient recovery phase. 
These abnormalities were not observed in any of the control 
iPSC- CMs after ISO stimulation. The amplitude of the Ca2+ tran-
sients (F/F0 in R176Q: 2.2 ± 1.5 vs control: 2.7 ± 0.89; P = .63) was 
similar amongst the two groups (Figure 3E). However, the SR Ca2+ 
load was significantly lower in R176Q iPSC- CM (F/F0: 1.8 ± 0.37) 
compared with control iPSC- CMs (F/F0: 3.9 ± 0.64; P = .039), sug-
gesting that the oscillating SR Ca2+ release events interfere with SR 
Ca2+ refilling.
3.5 | Effect of EL20 Ca2+ sparks in iPSC- CMs
Ca2+ sparks were recorded using line- scan mode on a LSM880 
confocal microscope to determine the diastolic activity of RyR2 in 
iPSC- CMs following a 1- Hz conditioning pacing train. Because spon-
taneous contractions in the non- evoked iPSC- CM population can 
potentially confound diastolic Ca2+ releases, Ca2+ imaging was done 
only under evoked pacing conditions to profile the drug responses 
of EL20 in vitro. In the presence of 100 nmol/L ISO, iPSC with the 
R176Q mutation exhibited a higher Ca2+ spark frequency (CaSpF) 
(3.6 ± 0.45 sparks/100 μm/s) compared with iPSC from the control 
(1.2 ± 0.34 sparks/100 μm/s; P < .001) (Figure 4A,B). Next, a screen-
ing dose of 500 nmol/L of EL20 was applied to the cells to determine 
the effects of this RyR2 inhibitor on diastolic SR Ca2+ release events. 
In control iPSC- CMs, the CaSpF was not significantly affected by the 
F I G U R E  2   Systolic Ca2+ transients in control and R176Q proband- derived induced pluripotent stem cell- derived cardiomyocytes (iPSC- 
CMs) under baseline conditions. A, Confocal line- scan images (top) and Ca2+ transients (bottom) in iPSC- CMs from the proband with the 
R176Q variant and healthy control under baseline conditions. Red arrows indicate spontaneous SR Ca2+ release events that developed 
during the diastolic phase in PSC- CMs from the proband. Bar graph summarizing non- evoked B, Ca2+ transient amplitude and C, 10 mmol/L 
caffeine- induced SR Load under baseline conditions of control (black) and R176Q (red) iPSC- CMs. D, Confocal line- scan images (upper 
panel) and transients (bottom panel) showing intracellular Ca2+ handling loaded with fluro- 4- AM of evoked (1- Hz field stimulation) control 
vs R176Q iPSC- CMs at baseline. DADs were further exacerbated in stimulated R176Q iPSC- CMs. Bar graph summarizing evoked E, Ca2+ 
transient amplitude and F, 10 mmol/L caffeine- induced SR Load under baseline conditions. Open circles represent individual cells. Data 
presented as mean ± SEM (NS = not statistically significant)
6  |     WORD et al.
addition of EL20 (1.3 ± 0.44 sparks/100 μm/s; P = .92 vs vehicle). In 
contrast, in R176Q iPSC- CMs, EL20 significantly reduced the CaSpF 
by 78% (to 0.8 ± 0.45 sparks/100 μm/s; P < .001 vs vehicle).
3.6 | Dose- response of Ca2+ spark inhibition 
by EL20
To get a better sense of what drug concentrations are needed to inhibit 
mutant RyR2 channels, we assessed the effects of different doses of 
EL20 on CaSpF in evoked iPSC- CMs derived from the CPVT proband. 
The dose- response curve, which is based on inhibition of the CaSpF, 
was determined at concentrations ranging from 10−9 up to 10−4 mol/L 
(Figure 4C). Results from the sigmoidal dose- response curve deter-
mined that the half maximal inhibitory concentration (IC50) of EL20 is 
8.2 × 10−8 mol/L. Hence, EL20 was found to inhibit excessive SR Ca2+ 
release at low nanomolar concentrations that are clinically relevant.
3.7 | Absence of detrimental effects of EL20 on 
systolic SR Ca2+ handling
Since EL20 inhibits aberrant SR Ca2+ release through mutant RyR2, 
it is possible that this drug has unwanted effects on systolic SR 
Ca2+ transients consequently leading to unwanted side effects.21 
To address this concern, we measured the Ca2+ transient amplitude 
induced by field stimulation at 1- Hz in iPSC- CMs (Figure 5). The am-
plitude of the SR Ca2+ transient was not altered by EL20 in iPSC- CMs 
from the control (F/F0: 1.8 ± 0.46) compared to control + vehicle 
(F/F0: 1.9 ± 0.27; P = .91). Importantly, EL20 also did not alter the 
Ca2+ transient amplitude in R176Q iPSC- CMs (F/F0: 1.7 ± 0.20) com-
pared to R176Q + vehicle (F/F0: 1.9 ± 0.46; P = .79). Interestingly, 
treatment with EL20 prevented to occurrence of pacing- evoked 
Ca2+ oscillations (Figure 3D), consistent with inhibition of aberrant 
RyR2 SR Ca2+ leak. Thus, EL20 does not negatively affect the Ca2+ 
transient amplitude at the cellular level, as previously seen in the 
CPVT mouse model.12
4  | DISCUSSION
Catecholaminergic polymorphic ventricular tachycardia re-
mains a difficult to treat inherited cardiac disorder associated 
with arrhythmias provoked by adrenergic stress. As reviewed in 
great detail in this recent review article,9 various classes of anti- 
arrhythmic drugs with RyR2 inhibitory properties have been 
developed and some show great promise for the treatment of 
CPVT. Patient- derived induced pluripotent stem cell- derived 
F I G U R E  3   Effects of isoproterenol on systolic Ca2+ transients in control and R176Q- proband- derived induced pluripotent stem cell- 
derived cardiomyocytes (iPSC- CMs) under baseline conditions. A, Confocal line- scan images (top) and Ca2+ transients (bottom) in iPSC- CMs 
from the proband with the R176Q variant and healthy control in the presence of 100- nmol/L isoproterenol (ISO). Red arrows indicate 
spontaneous SR Ca2+ release events that developed during the diastolic phase in PSC- CMs from the proband. Bar graph summarizing non- 
evoked B, Ca2+ transient amplitude and C, 10 mmol/L caffeine- induced SR Load under baseline conditions of control (black) and R176Q (red) 
iPSC- CMs. D, Confocal line- scan images (upper panel) and transients (bottom panel) showing intracellular Ca2+ handling loaded with fluro- 
4- AM of evoked (1- Hz field stimulation) control vs R176Q iPSC- CMs in the presence of 100- nmol/L isoproterenol (ISO). SR Ca2+ oscillations 
were further exacerbated in stimulated R176Q iPSC- CMs. Bar graph summarizing evoked E, Ca2+ transient amplitude and F, 10 mmol/L 
caffeine- induced SR Ca2+ load in the presence of 100- nmol/L ISO. Open circles represent individual cells. Data presented as mean ± SEM 
(*P < .05; NS = not statistically significant)
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cardiomyocytes (hiPSC- CMs) offer a powerful cellular model to 
evaluate the potential effectiveness and safety of experimental 
drugs in a preclinical human cell model.22 In the present study, 
we developed and characterized a novel iPSC- CM cell line con-
taining an N- terminal variant R176Q in RyR2. Our studies re-
vealed evidence for abnormal diastolic SR Ca2+ release events 
in spontaneously beating and paced single iPSC- CMs contain-
ing the R176Q variant in RyR2. Moreover, tetracaine deriva-
tive EL20 was able to suppress these aberrant SR Ca2+ release 
events at low nanomolar doses, suggesting that EL20 and re-
lated compounds are promising agents for the treatment of 
CPVT patients.
4.1 | Preclinical CPVT models based on iPSC- CMs
Patient- specific induced pluripotent stem cell- derived cardiomyo-
cytes have emerged as a powerful model of inherited arrhythmia 
disorders after the development of stem cell reprogramming by 
Yamanaka et al23 iPSC- CMs containing various CPVT- associated 
RyR2 variants have been generated and studies using confocal imag-
ing and patch- clamping approaches. Most studies to date revealed 
altered intracellular Ca2+ handling, in particular during final stages of 
repolarization, and increased Ca2+ spark frequencies, in iPSC- CMs 
containing RyR2 variants.24 Consistent with clinical observations, 
the administration of β- adrenergic agonists exacerbated these Ca2+ 
abnormalities in most studies. Jung et al25 investigated intracellular 
Ca2+ handling in great detail in CPVT iPSC- CM and found evidence 
for increased diastolic SR Ca2+ leak as well as reduced SR Ca2+ store 
contents after tonic stimulation. Our studies revealed similar find-
ings including an increased SR Ca2+ spark frequency and reduced 
SR Ca2+ load after β- adrenergic stimulation. These data suggest that 
enhanced diastolic SR Ca2+ leak in particular during β- adrenergic 
stimulation is the primary mechanism underlying arrhythmia forma-
tion, rather than SR Ca2+ overload which has been proposed as one 
mechanism of CPVT by some authors.26,27
In this study, we developed iPSC- CMs derived from a 14- year- old 
girl with the same N- terminal RyR2 variant R176Q as the mouse 
model previously reported by us.13,18 The R176Q variant caused 
a highly penetrant and severe phenotype in this affected family 
(Figure 1). The father, who is negative for the RyR2 variant, was 
the donor for the control iPSC- CM cell line. Characterization of 
intracellular Ca2+ handling in the control iPSC- CMs revealed no 
F I G U R E  4   EL20 suppresses abnormal SR Ca2+ release events 
in induced pluripotent stem cell- derived cardiomyocytes (iPSC- 
CMs) derived from the catecholaminergic polymorphic ventricular 
tachycardia patient (CPVT) proband. A, Representative recordings 
of Ca2+ sparks in iPSC- CMs from the CPVT proband in the absence 
and presence of EL20 (500- nmol/L). B, Summary data showing that 
EL20 reduced the Ca2+ spark frequency (CaSpF) in stimulated iPSC- 
CM compared to vehicle treatment. C, Dose- dependence of Ca2+ 
spark frequency inhibition and IC50 determination of EL20 (n = 9- 
10 cells per group). Open circles represent individual cells. Data 
presented as mean ± SEM (*P < .05, **P < .01, and ***P < .001)
F I G U R E  5   Absence of detrimental effects on evoked systolic SR Ca2+ transients by EL20. A, Confocal line- scan images (top) and 
transients (bottom) showing intracellular Ca2+ transients recorded in induced pluripotent stem cell- derived cardiomyocytes (iPSC- CMs) 
loaded with fluro- 4- AM during 1- Hz field stimulation pacing in the presence 500- nmol/L EL20. B, Bar graph summarizing the Ca2+ transient 
amplitude in iPSCs from both the catecholaminergic polymorphic ventricular tachycardia patient proband and control individual. Open 
circles represent individual cells. Data presented as mean ± SEM (NS = not statistically significant.)
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abnormalities, confirming the specificity and validity of the CPVT 
iPSC- CM cell line. The iPSC- CM containing the R176Q variant exhib-
ited several distinct abnormalities in intracellular Ca2+ handling. In 
spontaneously beating as well as pacing cells, spontaneous SR Ca2+ 
release events were seen during the late and early Ca2+ reuptake 
phase of the Ca2+ transient. The events during early repolarization 
look similar to oscillatory events associated with EADs in other 
studies in which action potentials were measured in iPSC- CMs.28,29 
These events more predominantly seen following b- adrenergic stim-
ulation. In addition, aberrant SR Ca2+ release events were observed 
after or during the final repolarization phase, consistent with DADs. 
These findings are consistent with prior studies and recapitulate 
the CPVT phenotype within the iPSC- CM model.28 Patients with 
RyR2 variants can be susceptible to both EAD- and DAD- mediated 
arrhythmia mechanisms because membrane voltage is strongly influ-
enced by Ca2+- sensitive ionic currents, and, conversely, cellular Ca2+ 
loading is strongly influenced by Ca2+ voltage- dependent currents 
that can promote complex AP dynamics in the heart.30 The diastolic 
SR Ca2+ leak can activate the Na+/Ca2+- exchanger, leading to a net 
inward Na+ current that can depolarize the plasma membrane lead-
ing to an arrhythmogenic beat.
4.2 | EL20 prevents arrhythmogenic Ca2+ release 
events in CPVT iPSC- CMs
Several prior studies showed that iPSC- CMs derived from CPVT 
patients can be utilized to identify drug molecules that correct 
the cellular phenotypes associated with mutant RyR2.24 In prior 
work, we synthesized a novel tetracaine derivative known as EL20 
and tested its pharmacological properties in the RyR2- R176Q het-
erozygous mouse model of CPVT.13 EL20 prevented ventricular 
tachycardia in R176Q/+ mice. Another tetracaine derivative known 
as EL9 also suppressed VT in the R176Q/+ mouse model without 
adverse effects on cardiac contractility.12 In ventricular myocytes 
isolated from R176Q/+ mice, EL9 normalized the increased Ca2+ 
spark frequency with an IC50 of 13 nmol/L.
12 These findings in ven-
tricular myocytes isolated from a CPVT mouse model were quite 
similar to those reported for EL20 in iPSC- CMs carrying the iden-
tical RyR2 variant R176Q. The present study represents the first 
to characterize the effects of a tetracaine derivative with RyR2 
inhibiting activity (ie EL20) on intracellular Ca2+ handling proper-
ties in human cardiomyocytes. Our work reveals that EL20 can 
normalize intracellular Ca2+ handling at nanomolar concentrations 
and prevented cellular arrhythmogenesis in iPSC- CM from a CPVT 
patient (Figure S6). On the other hand, EL20 did not exhibit un-
wanted effects in control iPSC- CMs derived from the proband's 
father who is negative for the RyR2 variant. Moreover, EL20 did 
not affect systolic SR Ca2+ release as evidenced by unaltered Ca2+ 
transient amplitudes (Figure 5). Since there was no difference in SR 
Ca2+ load between control and R176Q cells under basal conditions 
(Figure 2C), we are quite confident that EL20 does not alter the SR 
Ca2+ load. Together, these findings indicate that EL20 directly in-
hibits diastolic SR Ca2+ release events through the R176Q mutant 
RyR2 channels.
Previous studies revealed that EL20 stabilizes hyperactive RyR2 
channels.13 The molecular mechanism underlying the therapeutic 
effects of EL20 is believed to involve stabilization of the mutant 
RyR2 channel from which calmodulin has been dissociated as a re-
sult of the CPVT variant.13 On the other hand, EL20 did not alter 
the activity of wild- type RyR2 channel to which normal amounts 
of calmodulin are bound.13 Future studies can be conducted to 
validate this model by overexpressing calmodulin or generating 
calmodulin variants that enhance its binding to RyR2 containing 
CPVT- associated variants. Regardless, the observation that EL20 
and likely other tetracaine derivatives only modulate RyR2 chan-
nels containing disease- associated variants is promising and sug-
gests that these drugs will lack significant side effects, in particular 
suppression of excitation- contraction coupling and reduced cardiac 
contractility.
5  | CONCLUSIONS
We found that iPSC- CMs derived from a CPVT patient carrying 
RyR2 variant R176Q display irregular spontaneous Ca2+ release 
events that are well- established triggers of arrhythmias. Our data 
show that EL20 eliminated cellular arrhythmias at nanomolar con-
centrations in the absence of obvious side effects on intracellular 
Ca2+ handling parameters examined in the iPSC- CMs. Therefore, 
EL20 is a promising lead compound for further drug development 
efforts that could potentially provide novel treatment options for 
the orphan disease CPVT. RyR2 inhibitors such as EL20 directly tar-
get the disease- causing molecular defect in patients with CPVT (ie 
leaky RyR2 channels) and could be more effective compared to beta 
blockers that work upstream in the beta- adrenergic receptor signal-
ling pathway that leads to RyR2 phosphorylation and exacerbation 
of SR Ca2+ leak during stress or exercise.31 In a patient with a very 
high arrhythmic burden, however, it might be beneficial to treat with 
both EL20 and beta blockers to prevent SR Ca2+ leak at multiple lev-
els in the signalling pathway. In conclusion, our patient- derived iPSC-
 CM model offers a promising platform for further research into the 
pathophysiological mechanisms of CPVT, as well as a safe tool for 
screening and optimizing drug therapy using novel RyR2 inhibitors.
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